Table 1.
Characteristics of participants in stage 1: development stage; stage 2: validation stage; and combined stages
| Characteristic | Stage 1: development, n = 618 | Stage 2: validation, n = 529 | Combined stages, n = 1147 |
|---|---|---|---|
| Practices (n= 10),a number of participants (range) | 21–98 | 25–92 | 21–98 |
|
| |||
| Participants | |||
| Female, n (%) | 420 (68.0) | 367 (69.4) | 787 (68.6) |
| Mean age (SD), years | 41.1 (7.6) | 41.9 (7.0) | 41.5 (7.3) |
|
| |||
| Prevalence of increased risk of: n (%) | |||
| Diabetes | 114/608 (18.8) | 99/519 (19.1) | 213/1127 (18.9) |
| Ischaemic heart disease | 80/617 (13.0) | 72/527 (13.7) | 152/1144 (13.3) |
| Breast cancer | 26/411 (6.3) | 22/361 (6.1) | 48/772 (6.2) |
| Colorectal cancer | 13/617 (2.1) | 12/527 (2.3) | 25/1144 (2.2) |
| Population risk for all conditions, % | 59.8 | 58.8 | 59.4 |
a
Practice data: List size (2009) – range 6355 to 19 791; mean = 9870. Location – urban 4; suburban 2; rural 4. Partnership size – range 4 to 12, mean = 7. Ethnic minorities – range 2.5% to 3.9%. SD = standard deviation.